EC grants marketing authorisation for Jyseleca to treat adults with moderate to severe active rheumatoid arthritis

EC grants marketing authorisation for Jyseleca to treat adults with moderate to severe active rheumatoid arthritis. (Credit: Jai79 from Pixabay)